PHK
MRSN

Point72 Hong Kong’s Mersana Therapeutics MRSN Stock Holding History

Point72 Hong Kong’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-606
Closed -$102K – 1085
2022
Q3 		$102K Buy
+606
New +$98.5K ﹤0.01% 1227
2022
Q2 		– Sell
-571
Closed -$57K – 2240
2022
Q1 		$57K Buy
571
+204
+56% +$23.8K ﹤0.01% 1305
2021
Q4 		$57K Buy
+367
New +$71.4K ﹤0.01% 1307
2021
Q3 		– Sell
-354
Closed -$120K – 2283
2021
Q2 		$120K Buy
354
+243
+219% +$92K ﹤0.01% 1278
2021
Q1 		$45K Buy
+111
New +$53.8K ﹤0.01% 1304
2020
Q3 		– Sell
-238
Closed -$139K – 1401
2020
Q2 		$139K Buy
+238
New +$81.3K 0.02% 571
2019
Q4 		– Sell
-41
Closed -$2K – 1348
2019
Q3 		$2K Buy
+41
New +$2.98K ﹤0.01% 874
2019
Q2 		– Sell
-28
Closed -$4K – 1296
2019
Q1 		$4K Buy
+28
New +$3.52K ﹤0.01% 837
2018
Q3 		– Sell
-27
Closed -$12K – 1079
2018
Q2 		$12K Buy
+27
New +$11.9K ﹤0.01% 640

Other funds holding MRSN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Point72 Hong Kong's MRSN Position: Q4 2022 in Review

Point72 Hong Kong sold out of Mersana Therapeutics (MRSN) in Q4 2022, closing a stake of 606 shares — an estimated $102K sold.

Point72 Hong Kong first reported a position in MRSN in Q2 2018 and held it in 9 quarters. The position peaked at $139K in Q2 2020. 152 funds tracked by Wall St. Rank hold MRSN as of Q4 2022.

  • Point72 Hong Kong reported no remaining Mersana Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 606 Mersana Therapeutics shares in Q4 2022, an estimated $102K.
  • Point72 Hong Kong first reported a position in Mersana Therapeutics in Q2 2018 and held it in 9 quarters.
  • Point72 Hong Kong's Mersana Therapeutics position peaked at $139K in Q2 2020.
  • 152 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.